%0 Journal Article
%K Adolescent
%K Adult
%K Humans
%K Ad26COVS1/adverse effects
%K BNT162 Vaccine/adverse effects
%K Cohort Studies
%K COVID-19/epidemiology/prevention & control
%K *COVID-19 Vaccines/adverse effects
%K *Thrombocytopenia/epidemiology
%K *Thromboembolism/epidemiology
%K *Thrombosis/epidemiology
%K Venous Thrombosis/epidemiology
%B Bmj
%D 2022
%G eng
%M 36288813
%P e071594
%R 10.1136/bmj-2022-071594
%T Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US
%V 379
%2 PMC9597610 at www.icmje.org/disclosure-of-interest/ and declare: support from the EMA for the submitted work; DP-A receives funding from the UK National Institute for Health Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. XL receives the Clarendon Fund and Brasenose College scholarship (University of Oxford) to support her DPhil study. DP-A’s research group has received research grants from the EMA; Innovative Medicines Initiative; and Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca, and UCB Biopharma. LHJ works for a research group who receives unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chiesi, Astra-Zeneca, Amgen, Janssen Research and Development. PR works for a research group who receives unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chiesi, Astra-Zeneca, Amgen, Janssen Research and Development. CC has no conflicts of interest. None of these declarations relate to the content of this paper.
%7 2022/10/27
%@ 0959-8138 (Print)
0959-8138